Erythropoietin and intravenous iron in PBM.
Study Goal
The researchers aimed to evaluate the role of iron supplementation, either oral or intravenous, with or without erythropoietin, in optimizing preoperative hemoglobin for patients with anemia.
Results Summary
The study suggests that iron supplementation, particularly intravenous iron, along with erythrocyte stimulating agents (ESAs), can effectively optimize preoperative hemoglobin and red blood cell mass in anemic patients. Different formulations of intravenous iron and the indications/contraindications for ESAs are discussed.
Population
Preoperative patients with anemia.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
iron supplementation, either oral or intravenous | increase | preoperative hemoglobin | patient with anemia | - | optimization | #1 |
iron supplementation, either oral or intravenous | increase | hemopoiesis | patient with anemia | - | maximizing | #2 |
iron supplementation, either oral or intravenous | increase | RBC mass | patient with anemia | - | maximizing | #3 |
erythrocyte stimulating agents (ESAs) such as erythropoietin | increase | preoperative hemoglobin | patient with anemia | - | optimization | #4 |
erythrocyte stimulating agents (ESAs) such as erythropoietin | increase | hemopoiesis | patient with anemia | - | maximizing | #5 |
erythrocyte stimulating agents (ESAs) such as erythropoietin | increase | RBC mass | patient with anemia | - | maximizing | #6 |
The concept of patient blood management is such that if a patient with anemia can be identified in the pre-operative period, therapeutic modalities can be targeted to that patient who might benefit from such treatment. Management strategies include the optimization of preoperative hemoglobin by maximizing hemopoiesis and RBC mass. This can best be achieved with the use of iron supplementation, either oral or intravenous, with or without the use of erythrocyte stimulating agents (ESAs) such as erythropoietin. The use of i.v. iron and ESAs is reviewed. Different i.v. iron formulations available are discussed along with current indications and contraindications for the use of ESAs.